Purpose: Multiuse of the G-probe transscleral cyclophotocoagulation (TSCPC) device can lead to contamination. We evaluated the mechanical stability and clinical efficacy of a disposable sterile barrier for the G-probe footplate.
Methods: We measured diode laser output with and without the G-probe barrier both before and after cadaver TSCPC (18 shots at 2000 mW for 2000mS). Qualitative analyses of the laser aiming beam were made before each trial in the barrier and nonbarrier state. After each trial, the G-probe barrier was examined for microperforations and footplate for debris and/or damage. Microbiology was taken on the cadaver eye and the G-probe before and after 20 cycles. Histologic analysis after TSCPC with and without barrier was carried out on a cadaver eye.
Results: Qualitatively, laser focus dispersion was minimized by the G-probe cover. Mean (95% CI) laser output was measured for the nonbarrier, with barrier pre-TSCPC and with barrier post-TSCPC, respectively as 980 mW (899,1061), 1247 mW (1115, 1378), and 1240 mW (1132, 1347). The difference between the nonbarrier and barrier both preTSCPC and postTSCPC was statistically significant (df=2, F=36.26, P<0.01). No perforations in the G-probe barrier were evident and no debris or damage was detected on the G-probe. Pathology was consistent with earlier reports of TSCPC in cadaver eyes. Microbial segregation of the cadaver eye and the G-probe footplate was maintained.
Conclusions: The G-probe barrier is an effective and robust method to protect consecutive patients from contamination during TSCPC. Although energy levels were slightly higher in probes with barrier, histologic differences were not evident and the clinical significance of this finding is likely limited.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/IJG.0b013e3181e08109 | DOI Listing |
Exp Ther Med
April 2022
Department of Ophthalmology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Neovascular glaucoma (NVG) is a refractory form of glaucoma, associated with important morbidity, for which no consensus exists regarding the optimal choice of therapy. The primary aim of our study was to compare the performances of micropulse transscleral cyclophotocoagulation (MP-TSCPC) and continuous wave transscleral cyclophotocoagulation (CW-TSCPC) in the treatment of neovascular glaucoma (NVG). A total of 24 eyes for MP-TSCPC and 22 eyes for CW-TSCPC, all with NVG were included.
View Article and Find Full Text PDFJ Ophthalmol
February 2022
University of Zurich, Medical Faculty, Zurich, Switzerland.
Purpose: The aim of this study was to compare effectiveness and safety of MicroPulse transscleral laser therapy (MP-TLT) using the original MicroPulse P3® device and continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) using the G-Probe® device in glaucoma.
Methods: Spherical equivalent, intraocular pressure (IOP), best-corrected visual acuity (BCVA), and number of topical or oral ophthalmic pressure-reducing medications were registered at every time point, up to the last follow-up at 12 months. A complete slit-lamp examination was conducted to record the following complications: corneal edema, persistent ocular hypotony (IOP ≤5 mmHg) on two consecutive follow-up visits, choroidal detachment, phthisis bulbi, sympathetic ophthalmia, cystoid macular edema, or other abnormal ocular findings.
Int Ophthalmol
August 2022
Medical Faculty, University of Zurich, Zurich, Switzerland.
Purpose: The aim of this study is to address the safety and effectiveness of a second continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) treatment by comparing its outcome against a first CW-TSCPC treatment in the same patients with refractory glaucoma.
Methods: Twenty-one eyes with either primary or secondary glaucoma received a second CW-TSCPC laser session ≥ 3 months after the first treatment. Intraocular pressure (IOP), best-corrected visual acuity (BCVA), and number of topical or oral ophthalmic pressure-reducing medications were registered at every time point up to the last follow-up at 3 months.
Ophthalmol Glaucoma
September 2020
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Clin Ophthalmol
January 2020
Department of Ophthalmology, University of Hong Kong, Hong Kong.
Purpose: To compare the efficacy and safety of diode laser transscleral cyclophotocoagulation using either the long duration or short duration protocol.
Methods: Retrospective series of 23 consecutive patients with glaucoma who underwent continuous-wave diode laser transscleral cyclophotocoagulation from August 2016 to July 2018 at a tertiary hospital in Hong Kong. Laser pulse duration for the long and short duration protocols was defined as 3.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!